<DOC>
	<DOCNO>NCT02182674</DOCNO>
	<brief_summary>Study demonstrate comparability two puff Combivent hydrofluoroalkane ( HFA ) inhalation aerosol ( 18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff ) two puff market chlorofluorocarbon ( CFC ) contain product , Combivent ( CFC ) inhalation aerosol ( 18 mcg ipratropium bromide/103 mcg albuterol sulfate / per puff ) . The dose response profile , safety pharmacokinetics Combivent HFA formulation characterize .</brief_summary>
	<brief_title>A Confirmation Study Combivent HFA Inhalation Aerosol Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>1 . All patient diagnosis COPD must meet follow criterion visit 1 : Patients relatively stable , moderate severe airway obstruction baseline force expiratory volume one second ( FEV1 ) &lt; =65 % predict normal FEV1 / force vital capacity ( FVC ) &lt; =70 % . 2 . Patients must demonstrate &gt; = 015 % improvement baseline FEV1 within one hour inhalation two puff Combivent ( CFC ) inhalation aerosol ( 18 mcg ipratropium bromide/103 mcg albuterol sulfate per actuation ; exmouthpiece dose ) 3 . Male female patient 40 year age old . 4 . Patients must smoke history ten packyear . A packyear defined equivalent smoke pack 20 cigarette per day year . 5 . Patients must able perform technical satisfactory pulmonary function test . 6 . Patients must able trained proper use meter dose inhalator ( MDI ) 7 . All patient must sign informed consent form prior participation trial i.e. , prior prestudy washout usual pulmonary medication . 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 2 . Patients clinical relevant abnormal baseline hematology , blood chemistry urinalysis . If abnormality define disease list exclusion criterion , patient exclude . 3 . All patient serum glutamicoxaloacetic transaminase ( SGOT ) &gt; 80 IU/L , serum glutamic pyruvic transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL creatinine &gt; 2.0 mg/dL exclude regardless clinical condition . Repeat laboratory evaluation conduct patient . 4 . Patients total blood eosinophil count &gt; = 600/mmÂ³ . A repeat eosinophil count conduct patient . 5 . Patients recent history ( i.e. , one year less ) myocardial infarction . 6 . Patients recent history ( i.e. , three year less ) heart failure patient cardiac arrhythmia require drug therapy . 7 . Patients history cancer , treat basal cell carcinoma , within last five year . 8 . Patients history life threaten pulmonary obstruction , history cystic fibrosis bronchiectasis . 9 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion . 1 . 10 . Patients history asthma , allergic rhinitis atopy . 11 . Patients history active alcohol drug abuse . 12 . Patients know active tuberculosis . 13 . Patients upper respiratory tract infection COPD exacerbation six week prior screen visit ( Visit 1 ) screen visit visit 2 . 14 . Patients know symptomatic prostatic hypertrophy bladder neck obstruction . 15 . Patients know narrowangle glaucoma . 16 . Patients current significant psychiatric disorder . 17 . Patients regular use daytime oxygen therapy . 18 . Patients treat beta blocker medication , mono amine oxidase ( MAO ) inhibitor tricyclic antidepressant . 19 . Patients treat cromolyn sodium nedocromil sodium . 20 . Patients treat antihistamine . 21 . Patients use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose screen visit change screen visit visit 2 ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 22 . Patients treat oral beta adrenergic longacting betaadrenergics salmeterol ( Serevent ) formoterol two week prior screen visit screen visit visit 2 . 23 . Patients change therapeutic plan within last six week prior screen visit screen visit visit 2 , exclude change long act oral betaadrenergics short act inhaled betaadrenergics purpose trial . 24 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception . 25 . Patients know hypersensitivity anticholinergic betaagonist drug component either Combivent formulation . 26 . Patients take investigational drug within one month six half life ( whichever great ) prior screen visit . 27 . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>